Introduction
The term bone marrow transplantation has been replaced by the term haematopoietic cell transplantation (HCT). This is because the haematopoietic cells for transplantation now have several sources including bone marrow, cytopheresis of peripheral blood, and cord blood. HCT is now used to treat several haematological diseases (e.g., aplastic anaemia, b-thalassemia) and malignancies which otherwise are incurable. There are at present three major HCT procedures-these are myeloablative autologous, myeloablative and non-myeloablative allogeneic HCT. A non-myeloablative procedure for autologous HCT has been described. Renal injury and acute renal failure (ARF) are common complications of each of these procedures which affect both the morbidity and mortality of the recipient patient. The incidence and severity of the renal injury, however, are quite different in the three varieties of HCT. The purpose of this review, therefore, is to discuss the unique features of renal injury in autologous, myeloablative and non-myeloablative allogeneic HCT.
Autologous haematopoietic cell transplantation
With myeloablative autologous HCT, outpatient induction therapy is undertaken with high dose chemotherapy in an effort to eradicate the malignant cells [1] . This cytoreductive therapy is undertaken after haematopoietic cell harvest and storage of bone marrow or peripheral progenitor cells. Haematopoietic stem cells are collected from the bone marrow after repeated aspiration from the posterior iliac crest, or progenitor cells from peripheral blood by cytopheresis. The stem cells are then frozen at À196 C in 50 ml volume with 10% dimethmyl sulfoxide. After cytoreduction and the HCT transplant of the patient's own cells, reconstitution of the patient's bone marrow occurs after about 3 weeks. During that period of time the complications of HCT occur including infections, bleeding, and organ toxicities. The major difference between myeloablative autologous and myeloablative allogeneic HCT is that immunosuppressive treatment is not necessary with autologous HCT as graft rejection and graft vs host disease do not occur.
The first study to examine specifically renal injury in autologous HCT was in 232 breast cancer patients with positive nodes (Stage II/III, N ¼ 72) or metastases (Stage IV, N ¼ 160) [2] . The source of the transplanted cells was 35 from the bone marrow and 197 progenitor cells from peripheral blood. The outpatient induction therapy included adriamycin, flourouracil, and methotrexate. The high dose chemotherapy included cyclophosphamide (CPA), cisplatin, and carmustine (BCNU) or taxol with Mesna used at higher doses of CPA and BCNU. All patients received empirical intravenous antibiotics when the patient's absolute granulocyte count was <500/m and fever greater than 38. 3 C. This antibiotic coverage included gentamicin 2.5 mg/kg then 1.5 mg/kg IV q. 8 h; piperacillin 3 gm q. 4 h and vancomycin 1 gm q. 12 h. If the fever persisted for longer than 48 h, antifungal therapy with amphotericin or fluconazole was added.
Renal dysfunction was assessed as follows: before chemotherapy (day À7), before haematopoietic cell support (day À1), and post-haematopoietic support (days 7, 14, 21 and 3 months). The maximal serum creatinine was used for the glomerular filtration rate (GFR) calculation. Grade 0: decrement in GFR, as calculated by the Cockcraft and Gault formula, of <25% from baseline. Grade 1: a fall in GFR of more than 25% from baseline but a rise in serum creatinine of <2-fold. Grade 2: a fall in GFR of more than 25% and a rise in serum creatinine of >2-fold but without dialysis. Grade 3: same as Grade 2 but with dialysis.
There were no differences in age, body weight, baseline renal function, haematological parameters, plasma albumin, electrolytes, and pulmonary tests between the Stage II/III and Stage IV patients. The mean serum creatinine on day À7 was 0.85±0.01 mg/dl in these patients.
In Figure 1 are shown the results in renal function from day À7 to day 21. Grades 2/3 are considered severe renal dysfunction and are shown together. At day À1 the decrement in estimated GFR was comparable in Grade 2/3 and Grade 1. Thereafter, the decrement in GFR stabilized in the Grade 1 (n ¼ 81) but continued to decline in the Grade 2 and 3 patients (n ¼ 49). Dialysis was required in seven (3%) patients (Grade 3 dysfunction). In Table 1 are shown the nonrenal variables in the same patients by the grades of renal function. The patients with Grade 2/3 renal dysfunction had more sepsis, liver toxicity (i.e. more than 2-fold increase in hepatic enzymes), hepatic venous occlusive disease (VOD), and lung toxicity on univariate analysis. On multivariate analysis only lung toxicity (P<0.015), liver toxicity (P<0.001) and sepsis (P<0.015) were significantly associated with Grade 2/3 dysfunction. The mortality 60 days post-procedure was also significantly higher in the Grade 2/3 patients.
The overall severe renal dysfunction (Grade 2/3) in this autologous HCT study of 232 patients was 21%, as compared to previously reported 53% in myeloablative allogeneic HCT [3] . Hepatic VOD has been reported in allogeneic HCT to range from 22 to 54% [4, 5] while only 4.7% of patients in the present autologous HCT study had hepatic VOD. Hepatic VOD is defined as the occurrence of at least two of the following criteria within 20 days of transplantation: (1) total serum bilirubin >2 mg/dL, (2) hepatomegaly or right upper quadrant pain, and (3) sudden unexplained weight gain (>2% of baseline weight). Only two of 49 Grade 2/3 patients in the present study fulfilled the criterion of hepatorenal syndrome. Two-thirds of the autologous HCT Grade 2/3 patients were fluid overloaded during the period of chemotherapy. Finally, in the present autologous HCT study the mortality at 60 days postprocedure was only 7%, a figure significantly below the reported mortality in studies in which both patients receiving allogeneic and autologous HCT were included [3] [4] [5] . Autologous HCT, however, cannot be used in patients who have bone marrow involvement with the malignancy. Another potential drawback of myeloablative autologous HCT is the lack of graft vs tumour effect which may lead to an increased risk of relapse. With the failure to demonstrate an advantage of autologous HCT for patients with breast cancer and positive nodes or metastatic disease as compared to high-dose chemotherapy alone, the use of autologous HCT has been decreasing while allogeneic HCT is increasing (www.ibmtr.org/summaryslides).
Allogeneic myeloablative stem cell transplantation
A study was undertaken at the University of Colorado to evaluate the occurrence and severity of renal injury in 88 patients receiving myeloablative allogeneic HCT [6] . The same grades of renal function loss (Grade 0-3) were used as followed in the above autologous HCT study. The estimated GFR was calculated in the allogeneic study using the MDRD equation. The haematopoietic cell support included bone marrow or peripheral stem cells from related donors in 50% of patients and from unrelated donors in 17% of donors. Cryopreserved umbilical cord blood was used as a source of haematopoietic progenitor cells in the remaining 33% of patients. The same antibacterial prophylaxis for neutropenia and empiric treatment of fever, as in the above autologous study, was also used in the allogeneic HCT patients. After 48 h of fever, antifungal therapy with amphotericin (0.6 mg/kg/day) was instituted. In contrast to autologous HCT, immunosuppressive therapy was necessary in the myeloablative allogeneic HCT patients due to T-cell response against minor histocompability antigens. In this regard, beginning one day before the HCT, prophylaxis for graft vs host disease (GVHD) was initiated with cyclosporine (CsA) and methotrexate or CsA and prednisone. This immunosuppressive therapy also prevented rejection of the donor haematopoietic cells. The goal for CsA whole blood levels was 350-400 mg/ml. The malignancies that were treated and the high dose conditioning regimens used to ablate the malignant and bone marrow cells are shown in Table 2 .
There was no significant difference in the characteristics of the patients receiving the different conditioning regimens, i.e. with or without total body irradiation (TBI); with or without cyclophosphamide. The mean baseline GFR of the patients on day À7 was 110±25 ml/min/m 2 . Of the 88 patients, 81 (92%) had a decrease in estimated GFR (i.e. Grade 1-3). When considering only severe renal dysfunction (Grade 2 and 3) 69% of patients had a significant decline in renal function. This compares with 21% with severe renal dysfunction in the autologous HCT study [2] . In Figure 2 is shown the decline in creatinine clearance after the myeloablative allogeneic HCT. There was no statistically significant difference between the conditioning regimen or the type of malignancy treated and the occurrence of severe renal dysfunction or mortality. The overall rate of mortality at 2 months was 35% (31 of 88 patients) and 58% (51 of 88 patients) at 6 months for the myeloablative allogeneic HCT. The Grade 3 patients who were dialyzed had a very high mortality (24/29, 82.7%) as has been previously reported [3, 4] . There was also an 87.5% mortality among the patients receiving ventilator support. The patients with severe renal dysfunction had significantly higher frequencies of sepsis, hepatic toxicity (>2Â increase in AST and ALT), hepatic VOD and lung toxicity. Overall, 93% of the patients had some degree of hepatotoxicity. There was no significant difference between Grade 0-1 vs Grade 2 and 3 with respect to aminoglycoside and amphotericin therapy. There was also no difference between CsA blood levels and the grade of renal dysfunction or mortality.
In Table 3 are shown the differences in the rates of renal dysfunction and mortality in myeloablative autologous and allogeneic HCT from patients at the University of Colorado. There was significantly more severe renal dysfunction, hepatic VOD and lung toxicity with allogeneic HCT. The mortality rates were also much higher with the allogeneic transplantations. It should be noted that the autologous HCT and allogeneic HCT have been compared mainly for conceptual purposes. The two studies have been performed over different time periods and also the influences of differing underlying malignancies and conditioning regimens cannot be excluded.
Non-myeloablative allogeneic haematopoietic stem cell transplantation
Because of the organ toxicity and high mortality of myeloablative HCT, the procedure is generally only available to younger patients without co-morbid disease. Since the occurrence of malignancies increases with age, there was a need to develop a less toxic HCT for older patients with malignancies who were not qualified for myeloablative allogeneic HCT. Thus, the non-myeloablative HCT approach has been initiated [7, 8] . This procedure entails the use of a lowdose, conditioning regimen designed not to eradicate the malignant cells but rather to provide sufficient immunosuppression to allow the engraftment of the HCT. The hypothesis is that the engrafted haematopoietic stem cells will cause an immunological graft vs malignancy response which would destroy the tumour cells. There were several observations which support this immunological approach against malignancies [9] . Specifically, an increased risk of relapse has been observed with myeloablative allogeneic HCT in twins and after T-cell depleted transplants [10, 11] . An induction of remissions has also been observed by a donor lymphocyte infusion in patients who had relapsed after allogeneic HCT [12] . Lastly, donor-derived T-cell clones against malignant cells have been demonstrated [13] . The most characterized conditioning regime for non-myeloablative (mini-allo) HCT employs low dose total body radiation (TBI) (2 Gy)±IV fludarabine (30 mg/m 2 /day). This regime is less toxic than myeloablative allogeneic HCT and thus can be used in older, less healthy patients with lymphatic or haematological malignancies [7, 8] .
Mixed chimerism is an essential first step in the goal of the non-myeloablative HCT to cure malignancies. Mixed haematopoietic chimerism is when two haematopoietic systems co-exist in the same individual as occurs in the recipient of an allogeneic HCT. In non-malignant disorders mixed chimerism may be beneficial for diseases such as beta thalassemia, sickle cell disease, aplastic anemia, autoimmune diseases as well as organ graft survival. Development of full donor chimerism, however, is essential for cure of haematological malignancies in the recipient [9] . Mixed chimerism in the recipient is defined as the detection of donor T cells (CD3þ) of 95% or less of the total T-cell population. Table 4 outlines the treatment plan of the Fred Hutchinson Research Institute for the non-myeloablative HCT for malignancies. Cyclosporine was given orally for posttransplant immunosuppression and the levels were targeted to the upper therapeutic range of 500 ng/ml until day 35. The treatment is initiated on an outpatient basis and to patients only admitted to control transplant complications. Cytoreduction with hydroxyurea may be necessary to suppress the white blood cell count to <10 000/m/prior to TBI.
While the non-myeloablative allogeneic HCT procedure has been shown to have fewer complications than the myeloablative allogeneic HCT, such as cytomegalovirus infection, only recently was the frequency and severity of renal dysfunction reported. In a study of 253 patients from four centres (Fred Hutchinson and University of Washington; City of Hope; Stanford University; and University of Colorado), severe renal failure (Grade 2 and 3) occurred in 40.4% of the patients over a 3 month period, a value significantly less than the 69% observed in the myeloablative allogeneic HCT [3, 14] . Also, only 4.4% of patients needed dialysis, whereas in an earlier study of conventional (i.e. myeloablative) allogeneic HCT dialysis was required in 33% of patients [3, 14] . These findings occurred even though the non-myeloablative patients were significantly older (53 vs 23 years) and had more co-morbidity. The overall mortality in this non-myeloablative HCT study was 34% at 1 year as compared to 58% in the study of myeloablative allogeneic HCT discussed earlier [6, 14] .
Most of the acute renal failure in the nonmyeloablative study occurred within the first 3 months. Baseline characteristics and co-morbidities did not predict which patients would and would not develop renal dysfunction. The specific calcineurin inhibitor, cyclosporine (n ¼ 238) or tacrolimus (n ¼ 15), used for immunosuppression did not appear to make a difference in the frequency or severity of the renal failure. Interestingly, although a very small number of the 253 patients received haematopoietic cells from the bone marrow (4.3%) as compared to peripheral blood haematopoietic cells stimulated by granulocyte colony stimulated factor (95.7%), severe acute renal failure (Grades 2 and 3) occurred more frequently in the patients receiving the haematopoietic cells from the bone marrow as compared to peripheral blood (7.8 vs 2%, P<0.02). After controlling for other variables, the requirement for ventilatory support was associated with a 10-fold increase in the incidence of ARF. This was the strongest correlation in the multivariate analysis for renal dysfunction. Pre-existing diabetes was also weakly associated with renal dysfunction. Figure 3 shows that as renal dysfunction becomes more severe patient survival declines with the non-myeloablative HCT. Patients who had acute renal failure had a significantly higher mortality at 6 months (29.4 vs 16.5%, P<0.05) and at 1 year (42.1 vs 28.5%, P<0.05) as compared to those without kidney dysfunction. The cause of the renal dysfunction in this non-myeloablative allogeneic HCT study appeared to be multifactoral, including immunosuppression and sepsis, GVHD, drug toxicity, and TBI. In contrast to myeloablative allogeneic HCT, hepatic VOD and hemolytic uremia syndrome/thrombotic thrombocytopenic purpura were virtually absent in this group of mini-allo treated patients. In summary, the consideration of renal injury and dysfunction with HCT must involve the specific procedure used. Severe ARF occurs with all three varieties of HCT. However, in our studies the frequency of ARF (Grade 2 and 3) increases significantly from myeloablative autologous (21%) to non-myeloablative allogeneic (40%) to myeloablative allogeneic (69%). This increase in ARF correlates with a parallel increase in mortality from 7 to 34% to 58% at 6-12 months as well as progressive multiorgan involvement. With all three HCT procedures, the combination of ARF and dialysis, particularly with mechanical ventilation, the mortality increases to greater than 80%.
Thus, efforts to decrease the frequency and severity of ARF in both myeloablative and non-myeloablative allogeneic HCT should be pursued in order to decrease morbidity and mortality in these patients. Nephrologists should be involved early in the care of the patient receiving allogeneic HCT to identify small decrements in renal function, assist in fluid balance and medication dosing. Guidelines for timing, dose duration and modality of dialysis for ARF in the setting of HCT are clearly needed. Also, future studies need to identify interventions and strategies that will focus on decreasing ARF and subsequent mechanical ventilation following HCT.
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